Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer
- PMID: 27281650
- DOI: 10.1001/jamaoncol.2016.1291
Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer
Abstract
Importance: While adjuvant hormonal therapy (HT) reduces mortality for women with nonmetastatic breast cancer, nonadherence to HT is common.
Objective: We investigated the association between patterns of prior nonadherence to medications for chronic conditions with HT nonadherence.
Design, setting, and participants: For this retrospective cohort study, the MarketScan database was scanned for women 18 years and older who had been diagnosed with nonmetastatic breast cancer between January 1, 2010, and December 31, 2012, and who filled 2 or more prescriptions for tamoxifen and/or an aromatase inhibitor.
Main exposures and outcomes: Nonadherence to medications for 6 chronic conditions (hypertension, hyperlipidemia, gastroesophageal reflux disease, thyroid disease, diabetes, osteoporosis) in the 12 months before diagnosis was defined as a medication possession ratio (MPR) less than 80%. Nonadherence to HT was defined as an MPR less than 80% between the first and last prescription for HT up to 2 years.
Analysis: Multivariable logistic regression was used to determine the association between prior medication nonadherence and HT nonadherence.
Results: Of 21 255 women treated with adjuvant HT, 3314 (15.6%) were nonadherent, and age (<55 or ≥75 years vs 55-64 years), higher 30-day out-of-pocket costs, and increased comorbidities were associated with nonadherence. Women without prior medications for 1 of the chronic conditions (n = 7828 [37%]) had an 18.4% nonadherence rate to HT. Those who used 1 or more medication prior to HT and were adherent (n = 9223 [43%]) had a 9.8% nonadherence rate to HT (relative to those without prior medications: odds ratio [OR] 0.56; 95% CI, 0.50-0.61), while those who were nonadherent to their chronic medications (n = 4214 [20%]) had a 23.1% nonadherence rate to HT (OR 1.43; 95% CI, 1.30-1.58). Adherence and nonadherence for medications for each of the 6 medical conditions was associated with adherence or nonadherence for HT, respectively.
Conclusions and relevance: We found that nonadherence to medications for chronic conditions prior to HT was associated with greater nonadherence to oral HT in patients with breast cancer. Medication nonadherence history may play an important role in determining patients at risk for nonadherence to a subsequent medication for a different illness, such as HT, and a potential target for future interventions.
Similar articles
-
Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.J Clin Oncol. 2010 Sep 20;28(27):4120-8. doi: 10.1200/JCO.2009.25.9655. Epub 2010 Jun 28. J Clin Oncol. 2010. PMID: 20585090 Free PMC article.
-
Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer.J Clin Oncol. 2011 Jun 20;29(18):2534-42. doi: 10.1200/JCO.2010.33.3179. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606426 Free PMC article.
-
Risks of nonadherence to hormone therapy in Asian women with breast cancer.Kaohsiung J Med Sci. 2015 Jun;31(6):328-34. doi: 10.1016/j.kjms.2015.04.002. Epub 2015 May 6. Kaohsiung J Med Sci. 2015. PMID: 26043413 Free PMC article.
-
Adherence to long-term adjuvant hormonal therapy for breast cancer.Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):709-15. doi: 10.1586/erp.11.80. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 22098287 Review.
-
Adherence rates and correlates in long-term hormonal therapy.Vitam Horm. 2013;93:353-75. doi: 10.1016/B978-0-12-416673-8.00003-4. Vitam Horm. 2013. PMID: 23810015 Review.
Cited by
-
The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.J Natl Cancer Inst. 2022 Jun 13;114(6):871-877. doi: 10.1093/jnci/djac026. J Natl Cancer Inst. 2022. PMID: 35134972 Free PMC article.
-
Patterns of seizure prophylaxis after oncologic neurosurgery.J Neurooncol. 2020 Jan;146(1):171-180. doi: 10.1007/s11060-019-03362-1. Epub 2019 Dec 13. J Neurooncol. 2020. PMID: 31834582
-
Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer.Breast Cancer Res Treat. 2021 May;187(1):287-294. doi: 10.1007/s10549-020-06071-w. Epub 2021 Jan 9. Breast Cancer Res Treat. 2021. PMID: 33420863
-
Self-Management About Adjuvant Therapy in Breast Cancer Survivors: A Qualitative Study.Patient Prefer Adherence. 2022 Sep 23;16:2663-2681. doi: 10.2147/PPA.S379435. eCollection 2022. Patient Prefer Adherence. 2022. PMID: 36176347 Free PMC article.
-
Adherence to Oral Anticancer Medications Among Women With Breast Cancer in Africa: A Scoping Review.JCO Glob Oncol. 2023 Jan;9:e2100289. doi: 10.1200/GO.21.00289. JCO Glob Oncol. 2023. PMID: 36689700 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical